Baclofen in Parkinson's disease.

Abstract

In a controlled trial, baclofen (mean dose 45 mg daily) significantly increased disability from Parkinsonism in 12 patients with the long-term L-dopa syndrome. Peak dose choreoathetosis was not improved but a benefit was observed in all 4 patients with off-period dystonia. Adverse side effects were common and severe, and included visual hallucinations, vomiting and dizziness.